Depression Drugs Market Analysis and Demand with Forecast Overview to 2026

The depression drugs market, valued at over US$ 6.5 billion in 2017, is likely to witness bearishness in the near future, with a new report by Fact.MR estimating revenues to decline at a -2% CAGR. According to the study, although the prevalence rate of depression has gone up in the last decade, preference for cognitive behavior therapy (CBT) and awareness about the potential side effects has led to a decline in demand for depression drugs. The study finds that US continued to be at the forefront in terms of total depression drugs sold in 2018.

According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world. In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH). High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%). According to the Fact.MR study, although depression continues to be a major health issue, medical community and patients are encouraging a non-drug approach to reduce side effects and dependency. Healthcare providers and patients are focusing on cognitive behavior therapy (CBT) and mindfulness-based approaches to foster a long-term management of depression and other mental health issues.

After reading the depression drugs market report, readers get insight into:

  • Major drivers and restraining factors, opportunities and challenges, and the competitive landscape
  • New, promising avenues in key regions
  • New revenue streams for all players in emerging markets
  • Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions
  • Demand and uptake patterns in key industries of the depression drugs market
  • New research and development projects in new technologies in key regional markets
  • Changing revenue share and size of key product segments during the forecast period
  • Technologies and business models with disruptive potential

Popularity of Tech-based Mental Health Apps also Contributing to Low Sales

The study finds that demand for depression drugs is also witnessing a decline as end-users have more coping options at their disposal. The huge popularity of mental health apps, such as Headspace, Calm, Moodnotes, Pacifica, and SuperBetter has given patients more control over how they manage depression. Considering the growing body of research supporting the use of meditation and cognitive behavior therapy, the proliferation of tech apps has witnessed a spike in the recent years. The study finds that depression drugs market will continue to be influenced by these evolutions.

For a detailed industry outlook, Get the Report Sample at: https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

The depression drugs market report offers assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period. Key regions covered comprise:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Depression Drugs Market to Remain Concentrated in Developed Nations

North America and Europe are the two largest depression drugs market globally, owing to concentration of leading market players and increase in R&D of these drugs. While there has been a rising burden of mental illness such as bipolar I disorder and schizophrenia in China and India, lack of wide-ranging awareness regarding antidepressant medications (ADMs) is expected to negatively affect the growth of depression drugs market in the Asia Pacific region. Moreover, different therapies of depression are as efficacious as ADM and their effects are more enduring, which may create a hindrance in future expansion of depression drugs market, especially in Asia Pacific and Middle East & Africa.

The evaluation of the competitive landscape in the depression drugs market covers the profile of the following top players:

  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Pfizer, Inc.
  • AstraZeneca plc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Ltd
  • Sebela Pharmaceutical Inc.
  • Allergan USA, Inc.
  • Johnson & Johnson

To expand the understanding of opportunities in the ****** depression drugs market report looks at close quarters into the opportunities and new avenues in following key segments:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

In addition to understanding the demand patterns of various end users, the report on the depression drugs market also enumerates trends expected to attract investments by other various associated industries.

On the basis of drug class, the depression drugs market report offers insight into major adoption trends for the following segments:

  • Atypical antipsychotics
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • CNS stimulants
  • Others (Benzodiazepines and miscellaneous antidepressants)

The ****** depression drugs market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=3215

Some important questions that the depression drugs market report tries to answer exhaustively are:

  • Key strategic moves by various players in the depression drugs market in recent years with respect to product launches, deals and tie-ups, and mergers and acquisitions, and divestment of shares.
  • Which strategies will enable top players in the depression drugs market to expand their geographic footprints?
  • Which new business models are expected to change the course of growth of key regional markets in near future?
  • Which technologies will witness most attractive research investments and what will be the key sources of funding for startups and new entrants?
  • Which products segments have in recent years have seen new, lucrative application areas?